Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jul 26, 2021 11:17am
90 Views
Post# 33604322

RE:RE:RE:Prospectus Sup

RE:RE:RE:Prospectus SupWe still don't know why now or for what purpose the company needs the extra cash. Hopefully either company or LG will clarify why...If the extra money is to negotiate a better deal for either of the programs they might not start the selling anytime soon  until those negotiations are concluded or maybe not at all, unless they already have started talking with potential partners one would guess it would take a while, they have a ready to go protocol for NASH and hired a company to assist them with the deal, they said they have identified the potential partners and talks are ongoing despite all that deals take time. As for oncology it is a bit early as they need at the minimum the primary safety and possibly some efficacy read outs before they can present it to potential partners or maybe even the concluded phase 1 results. So if the money is a potential partnership most likely NASH first they won't need it for a while or perhaps not at all. If the money is to slowly starting to strengthen their balance sheet before converts are due then the selling can start at anytime I hope in that case they wait a bit longer until the oncology results are out the reason I say that is now almost four months later since they started  the dosing and based on the language used during the CC I believe what they know so far is all positive. Let the Cantor spread the potential good news and then sell.
I think some are overestimating the cost of the trials as a reminder it will be paid gradually and as for cancer the amount of cohorts participating in future phase will be far less than NASH thus less costly, my point is they don't need to start raising cash now for cancer. So the only reason they would start the selling sooner rather than later is converts. I think based on low volume now more than ever they need to get the retail onboard so we get a balanced supply and demand for those shares if and when they start the selling  also I really hope they won't start it prematurely like last offering.
<< Previous
Bullboard Posts
Next >>